PharmaEngine Inc 4162

Morningstar Rating

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

4162 is trading at a 861% premium.
Price
TWD 88.45
Fair Value
TWD 366.89
Uncertainty
Very High
1-Star Price
TWD 626.36
5-Star Price
TWD 94.79
Economic Moat
Kxjr
Capital Allocation

Trading Information

Previous Close Price
Day Range
52-Week Range
Bid/Ask
/
Market Cap
Volume/Avg
/

Key Statistics

Price/Earnings (Normalized)
35.13
Price/Sales
14.86
Dividend Yield (Trailing)
1.69%
Dividend Yield (Forward)
1.69%
Total Yield
1.69%

Company Profile

PharmaEngine Inc is a biopharmaceutical company engaged in the development of new drugs and therapeutic drugs for cancer. It is a specialty pharma company that adopts the no research, development-only model and the networked pharma model for new drug development. Its projects pipeline are: ONIVYDE was approved by the U.S. FDA, Taiwan FDA, and EMA for patients with gemcitabine-treated metastatic pancreatic cancer; and PEP07. It generates the revenue from Sales of goods.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
17

Comparables

Valuation

Metric
4162
6586
IMU
Price/Earnings (Normalized)
35.13
Price/Book Value
3.284.172.97
Price/Sales
14.86
Price/Cash Flow
33.66
Price/Earnings
4162
6586
IMU

Financial Strength

Metric
4162
6586
IMU
Quick Ratio
12.9823.033.66
Current Ratio
13.0723.433.86
Interest Coverage
1,511.77−730.54−321.34
Quick Ratio
4162
6586
IMU

Profitability

Metric
4162
6586
IMU
Return on Assets (Normalized)
8.92%−10.40%−67.09%
Return on Equity (Normalized)
9.41%−10.99%−77.26%
Return on Invested Capital (Normalized)
8.03%−12.17%−79.58%
Return on Assets
4162
6586
IMU

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk AS ADR
NVO
YlyqftqpnFst$512.4 Bil
Vertex Pharmaceuticals Inc
VRTX
TjxfkxtnJyfqx$117.5 Bil
Regeneron Pharmaceuticals Inc
REGN
NcdsvxgrWgcngl$111.6 Bil
Alnylam Pharmaceuticals Inc
ALNY
PxcwkdvpMvvnbk$34.4 Bil
argenx SE ADR
ARGX
NfqqvyghTfhw$31.7 Bil
BioNTech SE ADR
BNTX
QvcgvmplVppxl$29.2 Bil
Moderna Inc
MRNA
WpzgvmvrBvks$23.1 Bil
United Therapeutics Corp
UTHR
ZpcjxngFhck$15.8 Bil
Biomarin Pharmaceutical Inc
BMRN
VqdrtxpcbBntqw$13.2 Bil
Incyte Corp
INCY
QyncvmmrLhhzxdz$13.0 Bil

Sponsor Center